Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2025-06-11 00:00:00 ET · period of report 2025-06-09 · accession 0001104659-25-058580 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2025-06-11 | 2025-06-09+ | VRDN | Fairmount Funds Management LLC | Dir, 10% | M - OptEx | $11.80 | +14.1K | 3.46M | +0.4% | +$166.4K |
| DMI | 2025-06-11 | 2025-06-09+ | VRDN | Fairmount Funds Management LLC | Dir, 10% | M - OptEx | $0.00 | -14.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-09 | M | A | 1,600 | $7.80 | 3,447,413 | I Fairmount Healthcare Fund II LP | — | — | (F1) Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| 2 | Common | Common Stock | 2025-06-10 | M | A | 12,500 | $12.31 | 3,459,913 | I Fairmount Healthcare Fund II LP | — | — | (F1) Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-06-09 | M | D | 1,600 | $0.00 | 0 | I By: Peter Harwin | $7.80 · — to 2025-06-10 | 1,600 Common Stock | (F3) Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein. (F2) Beginning on October 27, 2020, the option vested monthly over a three-year period, subject to Peter Harwin's continued service to the Issuer. Mr. Harwin, a Managing Member of Fairmount and Fairmount GP II, served on the Issuer's Board of Directors through March 10, 2025. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-06-10 | M | D | 12,500 | $0.00 | 0 | I By: Peter Harwin | $12.31 · 2023-06-08 to 2025-06-10 | 12,500 Common Stock | (F3) Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein. |